185 related articles for article (PubMed ID: 35864270)
21. Real-life data on improvement of survival after perioperative chemotherapy versus surgery alone on resectable adenocarcinoma of the stomach - a single-center study.
Kuhnle PJ; Israel KF; Menges M
Z Gastroenterol; 2019 May; 57(5):606-610. PubMed ID: 31083749
[TBL] [Abstract][Full Text] [Related]
22. Survival outcomes in patients with gastric and gastroesophageal junction adenocarcinomas treated with perioperative chemotherapy with or without preoperative radiotherapy.
Tian S; Jiang R; Madden NA; Ferris MJ; Buchwald ZS; Xu KM; Cardona K; Maithel SK; McDonald MW; Lin JY; Curran WJ; El-Rayes BF; Behera M; Patel PR
Cancer; 2020 Jan; 126(1):37-45. PubMed ID: 31532544
[TBL] [Abstract][Full Text] [Related]
23. Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study.
Moussa O; Bhogal RH; Malietzis G; Fribbens C; Starling N; Gerlinger M; Watkins D; Chau I; Rao S; Cunningham D; Allum WH; Chaudry A; Kumar S
BJS Open; 2022 Jan; 6(1):. PubMed ID: 35195263
[TBL] [Abstract][Full Text] [Related]
24. The Role of Systemic Therapy in Resectable Gastric and Gastro-oesophageal Junction Cancer.
Cartwright E; Cunningham D
Curr Treat Options Oncol; 2017 Nov; 18(12):69. PubMed ID: 29143893
[TBL] [Abstract][Full Text] [Related]
25. Facing adenocarcinoma of distal esophagus and esophagogastric junction: a CROSS versus FLOT propensity score-matched analysis of oncological outcomes in a high-volume institution.
Lombardi PM; Pansa A; Basato S; Giorgi L; Perano V; Marano S; Castoro C
Updates Surg; 2023 Jun; 75(4):921-930. PubMed ID: 36991302
[TBL] [Abstract][Full Text] [Related]
26. Perioperative therapy with FLOT4 significantly increases survival in patients with gastroesophageal and gastric cancer in a large real-world cohort.
Möhring C; Mańczak A; Timotheou A; Sadeghlar F; Zhou T; Mahn R; Monin MB; Toma M; Feldmann G; Brossart P; Köksal M; Sarria GR; Sommer N; Lingohr P; Jafari A; Kalff JC; Strassburg CP; Gonzalez-Carmona MA
Int J Cancer; 2023 Aug; 153(3):609-622. PubMed ID: 36919950
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of nutritional markers in metastatic gastric and esophageal adenocarcinoma.
Ma LX; Taylor K; Espin-Garcia O; Anconina R; Suzuki C; Allen MJ; Honorio M; Bach Y; Allison F; Chen EX; Brar S; Swallow CJ; Yeung J; Darling GE; Wong R; Kalimuthu SN; Jang RW; Veit-Haibach P; Elimova E
Cancer Med; 2021 Jan; 10(1):199-207. PubMed ID: 33295697
[TBL] [Abstract][Full Text] [Related]
28. Perioperative FLOT chemotherapy plus surgery for oligometastatic esophagogastric adenocarcinoma: surgical outcome and overall survival.
Runkel M; Verst R; Spiegelberg J; Fichtner-Feigl S; Hoeppner J; Glatz T
BMC Surg; 2021 Jan; 21(1):35. PubMed ID: 33435947
[TBL] [Abstract][Full Text] [Related]
29. Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma.
Bayraktar UD; Bayraktar S; Hosein P; Chen E; Koniaris LG; Rocha-Lima CM; Montero AJ
Med Oncol; 2012 Sep; 29(3):1707-10. PubMed ID: 22033912
[TBL] [Abstract][Full Text] [Related]
30. Oxaliplatin in perioperative chemotherapy for gastric and gastroesophageal junction (GEJ) adenocarcinoma.
Fritsch R; Hoeppner J
Expert Rev Gastroenterol Hepatol; 2019 Apr; 13(4):285-291. PubMed ID: 30791774
[TBL] [Abstract][Full Text] [Related]
31. Perioperative EOX treatment in operable locally advanced gastroesophageal adenocarcinoma: Prediction of tumor response by FDG -PET and histopathology.
Vihervaara H; Ålgars A; Kemppainen J; Sundström J; Ristamäki R; Salminen P
Surg Oncol; 2019 Mar; 28():42-49. PubMed ID: 30851910
[TBL] [Abstract][Full Text] [Related]
32. CROSS or FLOT in Distal Esophageal and Gastroesophageal Cancer.
Karadag I; Karakaya S; Ates O; Cakmak Oksuzoglu OB
J Coll Physicians Surg Pak; 2021 Mar; 31(3):326-329. PubMed ID: 33775025
[TBL] [Abstract][Full Text] [Related]
33. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
Glatz T; Bronsert P; Schäfer M; Kulemann B; Marjanovic G; Sick O; Hopt UT; Zirlik K; Makowiec F; Hoeppner J
Eur J Surg Oncol; 2015 Oct; 41(10):1300-7. PubMed ID: 26253194
[TBL] [Abstract][Full Text] [Related]
34. Postoperative and Pathological Outcomes of CROSS and FLOT as Neoadjuvant Therapy for Esophageal and Junctional Adenocarcinoma: An International Cohort Study From the Oesophagogastric Anastomosis Audit (OGAA).
Oesophago-Gastric Anastomotic Audit (OGAA) Collaborative
Ann Surg; 2023 May; 277(5):e1026-e1034. PubMed ID: 35099168
[TBL] [Abstract][Full Text] [Related]
35. Preferred neoadjuvant therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis.
Grizzi G; Petrelli F; Di Bartolomeo M; Viti M; Texeira Moraes M; Luciani A; Passalacqua R; Ghidini M; Tomasello G; Baiocchi GL; Celotti A
Gastric Cancer; 2022 Sep; 25(5):982-987. PubMed ID: 35704113
[TBL] [Abstract][Full Text] [Related]
36. FLOT or CROSS for gastroesophageal junction cancers-is the debate over yet?
Shariff B; Mehta R
Chin Clin Oncol; 2023 Jun; 12(3):24. PubMed ID: 37303220
[TBL] [Abstract][Full Text] [Related]
37. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer.
Tan BH; Brammer K; Randhawa N; Welch NT; Parsons SL; James EJ; Catton JA
Eur J Surg Oncol; 2015 Mar; 41(3):333-8. PubMed ID: 25498359
[TBL] [Abstract][Full Text] [Related]
38. Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study.
Nappo F; Fornaro L; Pompella L; Catanese S; Lavacchi D; Spallanzani A; Cappetta A; Puzzoni M; Murgioni S; Barsotti G; Tirino G; Pellino A; Vivaldi C; Strippoli A; Aprile G; Di Donato S; Mazza E; Prisciandaro M; Antonuzzo L; Zagonel V; Cascinu S; De Vita F; Lonardi S
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6601-6611. PubMed ID: 36795195
[TBL] [Abstract][Full Text] [Related]
39. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.
Zhang X; Liang H; Li Z; Xue Y; Wang Y; Zhou Z; Yu J; Bu Z; Chen L; Du Y; Wang X; Wu A; Li G; Su X; Xiao G; Cui M; Wu D; Chen L; Wu X; Zhou Y; Zhang L; Dang C; He Y; Zhang Z; Sun Y; Li Y; Chen H; Bai Y; Qi C; Yu P; Zhu G; Suo J; Jia B; Li L; Huang C; Li F; Ye Y; Xu H; Wang X; Yuan Y; E JY; Ying X; Yao C; Shen L; Ji J;
Lancet Oncol; 2021 Aug; 22(8):1081-1092. PubMed ID: 34252374
[TBL] [Abstract][Full Text] [Related]
40. FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group.
Hofheinz RD; Merx K; Haag GM; Springfeld C; Ettrich T; Borchert K; Kretzschmar A; Teschendorf C; Siegler G; Ebert MP; Goekkurt E; Mahlberg R; Homann N; Pink D; Bechstein W; Reichardt P; Flach H; Gaiser T; Battmann A; Oduncu FS; Loose M; Sookthai D; Pauligk C; Göetze TO; Al-Batran SE
J Clin Oncol; 2022 Nov; 40(32):3750-3761. PubMed ID: 35709415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]